CIRM Leadership

Maria T. Millan, President and CEO

Maria Millan, President and CEO

Maria T. Millan is the President and CEO of the California Institute for Regenerative Medicine (CIRM). Under her leadership, CIRM has generated a robust and growing portfolio as a patient-centric funder, partner, accelerator, and de-risker for over 1,000 projects in basic, translational, and clinical research, as well as infrastructure and education programs.

After completing her education and training at Duke, NJ Medical School, Harvard and Stanford, Dr. Millan served as an Associate Professor and Director of Pediatric Organ Transplantation at Stanford. She then joined the private sector where she helped to launch the first in-human neural stem cell clinical trial performed in children afflicted with a devastating and fatal neurodegenerative disease.

In 2012, Dr. Millan joined CIRM where she led the implementation of CIRM’s unique acceleration model, the formation of infrastructure to support translational and clinical research, and the growth of CIRM’s clinical stage portfolio. In 2017, she took on the role of President and CEO and successfully led  the Agency to accomplish all of its goals under the 5-year Strategic Plan including the discovery of 50 new drug candidates, the growth of its clinical portfolio to 76 predominantly first in-human trials, and the training of hundreds of students and scholars in regenerative medicine. In 2020, with CIRM funding running out, its future uncertain, and at the height of the pandemic, she led the Agency to continue its commitment to funding and supporting important scientific and clinical programs. In November 2020, with the reauthorization of CIRM through the passage of a $5.5 billion bond initiative (Prop 14), she led the CIRM team to immediately relaunch its programs, expand its highly skilled team, and develop and implement a bold Strategic Plan to accelerate world class science to deliver transformative regenerative medicine therapies to a diverse California and world. 


Jonathan Thomas, Chairman, Independent Citizens’ Oversight Committee (ICOC)

Jonathan Thomas, Chairman of CIRM BoardJon Thomas is a Co-Founding Partner at Saybrook Capital (“Saybrook”), an investment banking and private equity firm based in Santa Monica, California.

Long interested in the biological sciences, Thomas majored in Biology and History at Yale, where he graduated summa cum laude. As a George C. Marshall Scholar at Oxford, he then earned a PhD with a medical focus in Commonwealth History. He subsequently returned to Yale for a JD at the Yale Law School. While there, Thomas retained an involvement with biology by teaching courses on the legal implications of genetic engineering and the impact of disease on history.

Thomas has a long-standing commitment to patient advocacy. He spent more than 15 years on the Board of the Crippled Children’s Society of Southern California and served as chair for four years. The organization, now called AbilityFirst, assists children with spinal cord injuries and mental disabilities that could be targets of stem cell therapies. Thomas is an Honorary member of the AbilityFirst Board.  

See his full bio here


Senator Art Torres (Ret.), Vice-Chair

Senator Art Torres (Ret.), Vice-ChairSenator Art Torres (Ret.) was unanimously elected statutory Vice Chair of the Independent Citizens Oversight Committee, the governing Board of the California Institute of Regenerative Medicine (CIRM).  He is also Chair of the Governance Committee.  He is a colon cancer and osteoarthritis survivor.

Between 1996 and 2009, Torres served as the Chair of the California Democratic Party. He previously served twenty years in the California Legislature, eight as a member of the State Assembly and twelve as a State Senator. Torres chaired the Senate Insurance Committee, Senate Toxics Committee, the Assembly Health Committee, and the Senate Joint Committee on Science and Technology.

He is currently on the Board and Vice Chairman of "One Legacy," an organ transplant foundation in the US headquartered in Los Angeles.

He was recently appointed by the California State Senate to the five member board of Covered California which oversees Obamacare in California. He also serves as a member of the Board of Trustees of the UC Santa Cruz Foundation.

Senator Torres authored the California Clean Water Drinking Act, Proposition 65, and created the sole toxic reporting repository that helps scientists determine environmental and health impacts “a data source that really no one else has on the planet.” On November 18th, 2010 he was sworn in by then Mayor Gavin Newsom, to a four year term on San Francisco’s Public Utilities Commission and later elected as its President before stepping down.

Senator Torres holds a Bachelor's Degree from UC Santa Cruz and a Juris Doctorate degree from UC Davis School of Law. He also served as a John F. Kennedy teaching fellow at Harvard University's John F. Kennedy School of Government.

He previously served as a German Marshall Fund Fellow and was recently appointed as the University of San Francisco Diversity Scholar Visiting Professor.

See his full bio here


Maria Bonneville, Vice President of Public Outreach and Board Governance 

Maria Bonneville, Vice President of Public Outreach and Board Governance

Maria Bonneville is the Vice President of Public Outreach and Board Governance at CIRM and has been with the agency since 2011. Maria is in charge of a team with a wide range of skills but a common goal, communicating CIRM’s mission to the public through the CIRM website, the blog and social media channels as well as in-person events. She works directly with the CIRM Board to advance CIRM’s mission and to lead the development and coordination of Board policies and procedures. She also works with California state legislators and staff members to keep the public up to date on the full scope of CIRM’s activities.

Before joining CIRM, Maria was the Special Assistant to former Treasurer Bill Lockyer at the California State Treasurer’s office where she represented the Treasurer in state business matters with the state and local government and the business community in the Bay Area. She was also the Northern California Finance Director for the Lockyer Committee and was responsible for fundraising programs for the re-election of California Attorney General Bill Lockyer for Treasurer. Maria also has extensive experience with product development, product marketing, E-commerce, and public relations.

She received a Bachelor of Arts in political sciences from the University of California Berkeley.


Rosa Canet-Avilés, Vice President of Scientific Programs

Rosa Canet-Avilés, Vice President of Scientific ProgramsRosa Canet-Avilés is the Vice President of Scientific Programs at CIRM and leads a team that actively works towards identifying the most promising basic and early stage research in stem cells and other areas related to regenerative medicine and enabling their success. Under her leadership, the Scientific Programs team manages a portfolio of hundreds of active programs that include basic mechanistic research, discovery, exploratory research, and identification of potential candidates for translational development. Rosa is also responsible for the internal and external collaborative networks and consortia that will result from the early-stage scientific programs managed by this group. Together with the rest of the leadership team, Rosa is responsible for the strategic alignment and connectivity with other CIRM programs (e.g., clinical networks, knowledge and data networks, registries, educational and communication portals) with the ultimate goal of translating all these efforts into cures.

Rosa is a familiar face at the agency, serving as a Science Officer with CIRM from 2008 to 2014. During that time, she helped oversee the development of CIRM’s Translational program, managed a broad portfolio of projects and organized workshops on Parkinson’s Disease and Autism amongst other. She brings nearly two decades of experience developing and leading multi-stakeholder initiatives across biopharma, government and nonprofit organizations. In her recent role as the Director of Strategic Alliances at the Eisai Center for Genetics Guided Dementia Discovery (G2D2), as part of the leadership team at G2D2, Rosa was responsible amongst other for the strategic planning of alliances and external innovation partnerships in the neurobiology business unit. As such, Rosa was instrumental in driving growth to the organization through the identification and management of external innovation opportunities. During the previous 7 years, Rosa was the Director of Neuroscience Research Partnerships at the Foundation for the National Institutes of Health (FNIH), Rosa was responsible for the development and management of the Neuroscience Research Partnership portfolio of projects and programs that includes: the Accelerating Medicines Partnership (AMP) for Alzheimer’s Disease (AMP-AD) 1 and 2, AMP Parkinson’s Disease (AMP-PD), AMP Schizophrenia (AMP SCZ), the Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) and the Biomarkers Consortium Neuroscience Steering Committee (BC NSC). Rosa managed different teams in coordination with NIH, FDA, non-profit organizations and industry leaders.

Rosa earned her PhD degree in neuroscience from the School of Medicine at Leeds University, UK. She also holds a BS in organic chemistry from the Central University of Barcelona.


Abla Creasey, Vice President of Therapeutics Development

Abla Creasey, Vice President of Therapeutics and Strategic InfrastructureAbla Creasey is the Vice President of Therapeutics Development. In this capacity, she leads all programs in Translational and Clinical development, with a focus on advancing these therapies to marketing approval. Abla has been instrumental in building and managing CIRM’S clinical portfolio of diverse therapeutic areas including oncology, neurology, ophthalmology, and others.  She has led the CIRM Therapeutics Team since 2018 and delivered on a key strategic goal to identify, recruit, and develop fifty innovative clinical stage projects and manage them to success. Eight of the current 64 FDA approved projects with Regenerative Medicine Advanced Therapies Designation are among the Therapeutics grants portfolio. Abla also oversees Translation, Clinical and Marketing Approval Advisory Panels that work with grantees on all aspects of product development including preclinical, clinical, regulatory, manufacturing, project management, and strategic topics.

Abla has extensive experience in research and development, including clinical trial strategy and operations, as well as biologics process development & manufacturing, regulatory, and overall strategic product development.  Prior to joining CIRM in 2016, she was at Johnson & Johnson for 12 years. While there, Abla held multiple senior level positions, including Senior Scientific Director in Pharmaceutical Development & Manufacturing Sciences (PDMS) at Janssen Therapeutics. Prior to that, she was an Executive Director, heading drug delivery, pharmacology, analytical characterization, clinical & quality at Advanced Technologies & Regenerative Medicine (ATRM), another J&J company. Prior to ATRM, Abla was Vice President of Biological Sciences at ALZA Corporation, where she headed discovery efforts in formulation, preclinical and oral drug delivery. Before joining ALZA in 2004, Abla held senior level positions in R&D, clinical development, and regulatory affairs within the biotechnology industry, including Chiron Corporation and Cetus Corporation. Abla received in 2008 the Ellis Island Medal of Honor for her biotechnology contributions. She served on the Mills College Board, Oakland, Ca, and the Dean of UC Berkeley School of Public Health Advisory Board. She has 23 patents and authored over 50 publications.

Abla received a B.S. in biology from the College of Notre Dame in Belmont, California, and earned her Ph.D. in medical microbiology from the University of California, Berkeley.  She completed a post-doctoral fellowship at the Stanford University School of Medicine in infectious disease, biochemistry, and immunology.


Kevin Marks, General Counsel

Kevin Marks, General CounselKevin Marks is CIRM’s General Counsel and is responsible for overseeing CIRM’s Legal and Human Resources Departments as well as other operational areas.  In his role, Kevin provides guidance to CIRM’s leadership, the Governing Board, and the entire CIRM team in developing strategies to implement CIRM’s mission. 

Kevin joined CIRM in June of 2021 after 14 years at Roche Diagnostics in both the therapeutics and diagnostics areas, serving as Vice President and Head of Legal and Compliance at Roche Molecular Solutions (encompassing molecular diagnostics, tissue diagnostics, and sequencing) and Vice President and General Counsel at Roche Molecular Diagnostics.  In these roles, Kevin oversaw a teams in general law, employment law, compliance and intellectual property and managed the business area’s global litigation portfolio, coordinated legal and compliance support for nine sites in the US, Europe and Africa, and directed the acquisition and legal integration of six startup companies. Prior to that, Kevin served in Roche’s pharmaceutical side for 9 years as Vice President, General Counsel at Roche Palo Alto, LLC. 

Kevin received his undergraduate AB degree at Lafayette College in International Affairs and Russian and his law degree at Villanova University.


Jennifer Mielnicki Lewis, Director of Grants and Operations

Jennifer Lewis is the Director of Grants & Operations at CIRM leading the Grants Management and Information Technology functions for the agency.  In this role she provides strategic operational and policy direction, ensures awardee funding is monitored and in compliance with appropriate regulations, identifies opportunities to streamline processes and enhance portfolio reporting, and oversees technology solutions to enable CIRM operations to work in a collaborative and fast-paced environment.  
 
Jennifer joined the grants management team at CIRM in 2016 and during that time has contributed to the rigorous grantmaking engine through portfolio oversight and management, implementing electronic grant records, database improvements and operationalizing the grantmaking of funding partnerships. In addition, during the wind-down of Proposition 71, Jennifer oversaw the administrative and research budgets ensuring that CIRM could make the most impact with the remaining funds.  
 
Before joining CIRM, Jennifer was a senior member of the program team at the Stuart Foundation where she made funding recommendations, created grantee communications, and developed system and process enhancements. Jennifer’s experience has focused on operational roles spanning the philanthropic, nonprofit, private and government sectors. She also has had experience in organizational development, project management, and financial analysis.
 
Jennifer received a Bachelor of Hospitality Administration from Boston University and holds a Master of Public Administration from the University of Illinois at Chicago.


Shyam Patel, Director of Business Development

Shyam Patel is Director of Business Development and is responsible for managing CIRM’s Industry Alliance Program and strategic partnerships. Shyam’s team engages with the biotech industry to create visibility for CIRM’s mission and to facilitate industry partnership and commercialization opportunities for CIRM’s portfolio. Shyam led the expansion of CIRM’s Industry Alliance Program to establish a collaborative network of venture investors, biotech companies and large biopharma partners. He also manages CIRM’s partnerships including the Cure Sickle Cell partnership with NHLBI, iPSC repository partnership with Fujifilm CDI and data sharing collaboration with Chan Zuckerberg Initiative.

Shyam joined CIRM in late 2016, initially as part of Dr. Sambrano’s Portfolio Development & Review team where he managed the application, review and approval processes for Discovery, Translational and Clinical Programs. Prior to CIRM, Shyam was CEO and Chief Science Officer for NanoNerve, Inc., where he and his team developed tissue engineered medical devices for tissue regeneration. He was also on the teaching faculty in Bioengineering at the University of California, Berkeley, where he taught undergraduate and graduate courses in biomaterials, stem cells and tissue engineering and medical device development.

Shyam received a B.S. in Bioengineering from the University of California, Berkeley, and a Ph.D. in Bioengineering from the Universities of California Berkeley & San Francisco.


Gil Sambrano, Vice President of Portfolio Development and Review

Gil Zambrano, Director of Portfolio Development and ReviewGil is the Vice President of Portfolio Dvelopment and Review and leads the team responsible for selecting the highest quality stem cell-based projects for CIRM funding from Discovery to Clinical programs.  His team builds and cultivates a world class team of expert reviewers and directs a rigorous review process through the governing board-appointed Grants Working Group (GWG).

Gil joined CIRM in 2005 as the first Scientific Officer. During his tenure, Gil has contributed to building the vision of CIRM by leading and advancing the scientific review process, constructing grants administration policies, guiding early development of the Grants Management System, and managing the training grant programs. He has been a key point of contact to help applicants and grantees identify appropriate partnering opportunities and navigate the CIRM solicitation and application process.  He leads the conduct of GWG review meetings and has been the primary liaison with patient advocate and scientific members of the GWG.

Prior to CIRM, he was an assistant professor in the department of Cellular and Molecular Pharmacology at UCSF. In 2001, Gil took on a notable position to coordinate efforts of the Alliance for Cellular Signaling, a multi-institutional and multi-disciplinary consortium of scientists led by the Nobel laureate, Alfred G. Gilman, whose goal is to understand the basic principles that regulate signal transduction in cells.

His scientific education includes a B.S. in biology from the University of Texas at El Paso and a Ph.D. in biomedical sciences from the University of California, San Diego. Gil trained as a postdoctoral fellow at the Cardiovascular Research Institute at the University of California San Francisco.


Pouneh Simpson, Director of Finance

Pouneh Simpson, Director of Finance

Pouneh Simpson is the Director of Finance and oversees CIRM’s accounting, budget, procurement, contracts and business services functions. Pouneh manages the strategic financial planning and financial forecasting of expenditures and receipts, including bond proceeds and commercial paper receipts. She reports quarterly to the ICOC and Finance Subcommittee on finance, budgeting and financial planning to ensure that the organization complies with Proposition 14 and all State of California laws and regulations. Pouneh also reports to the Citizens Financial Accountability Oversight Committee on an annual basis on the financial practices and performance of the CIRM. 

Pouneh started her state career as a Jesse Unruh Fellow in the State Assembly. Pouneh continued in the Executive Branch first at the Department of Finance and then at various state agencies in the areas of finance and administration. She was the Governor’s Appointee to the California Department of Veterans Affairs as the Chief Financial Officer of the Veterans Homes. She also served as Chief of Administration at the Office of Inspector General and State Personnel Board and Chief Financial officer of the California Prison Industry. 

She received a Bachelor of Arts in Sociology and Organizational Studies from the University of California Davis and Master of Public Administration from the University of Southern California.


Sean Turbeville, PhD, Vice President of Medical Affairs and Policy

Sean Turbeville, PhD, Vice President of Medical Affairs and Policy

Dr. Sean Turbeville has nearly 20 years of experience in Medical Affairs, creating strategies and teams for biopharma and digital healthcare companies. He has experience supporting the development of therapies in cancer, neurology, metabolic and genetic disorders and working with Regulatory Authorities such as the FDA, EMA, MHLW, and others.    

As CIRM's VP of Medical Affairs and Policy, Dr. Turbeville will oversee a Medical Affairs Team to develop healthcare policy, reimbursement strategy, post-market activities, and medical research. He will also oversee the expansion of the Alpha Stem Cell Clinics, The Community Care Centers of Excellence initiative, and the delivery of novel therapies to patients in underserved communities.    

Dr. Turbeville has a Ph.D. in Epidemiology from the University of Oklahoma Health Sciences Center, where he later taught courses as an Adjunct Associate Professor. He owns two global regulatory resources for biopharma, "The Global Regulatory Framework for Medical Information in the Pharmaceutical Industry" and "The Global Guide to Compassionate Use Programs." Before joining CIRM, Dr. Turbeville was the President of Matanzas Group, a Medical Affairs consultancy providing a range of Medical Affairs services to over 20 small, growing biopharmaceutical companies.  

Latest Press Releases

CIRM-funded research programs are helping turn stem cells into cures. Browse our press release archive below to find out the latest advances. For even more breaking news, visit our blog, The Stem Cellar.